NYU Langone Health

Migration, Crosslink

📖

NYU Langone Health

active

wiki page Created: 2026-04-02T07:20:10 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-new-york-university

📖 Wiki Page

institution2390 wordssynced 2026-04-02

NYU Langone Health is a world-class academic medical center located in New York City, comprising NYU Grossman School of Medicine and multiple affiliated hospitals. Founded in 1941, NYU Langone has established itself as a global leader in neuroscience research and clinical care, with particular strengths in Alzheimer's disease, Parkinson's disease, Lewy body dementia, and other neurodegenerative disorders. The institution's strategic location in New York City provides access to one of the most diverse patient populations in the world, enabling research that addresses the full spectrum of neurodegenerative diseases across different ethnic and demographic groups.

[@neurology]

<div class="infobox infobox-institution">
| NYU Langone Health | |
|---|--- |
| Location | New York, NY, USA |
| Type | Academic Medical Center |
| Founded | 1941 |
| Medical School | NYU Grossman School of Medicine |
| Hospitals | Tisch Hospital, Kimmel Pavilion, Rusk Rehabilitation |
| Website | [nyulangone.org](https://nyulangone.org) |
::

The institution houses the Alzheimer's Disease Research Center (ADRC), one of the NIH-funded Alzheimer's Disease Research Centers across the United States, as well as the Center for Brain Health, which focuses on cognitive enhancement and prevention strategies. The Institute for Neurology encompasses comprehensive programs in movement disorders, cognitive neurology, and neuroimaging, making NYU Langone one of the premier destinations for neurodegenerative disease research and patient care in the United States.

...

NYU Langone Health is a world-class academic medical center located in New York City, comprising NYU Grossman School of Medicine and multiple affiliated hospitals. Founded in 1941, NYU Langone has established itself as a global leader in neuroscience research and clinical care, with particular strengths in Alzheimer's disease, Parkinson's disease, Lewy body dementia, and other neurodegenerative disorders. The institution's strategic location in New York City provides access to one of the most diverse patient populations in the world, enabling research that addresses the full spectrum of neurodegenerative diseases across different ethnic and demographic groups.

[@neurology]

<div class="infobox infobox-institution">
| NYU Langone Health | |
|---|--- |
| Location | New York, NY, USA |
| Type | Academic Medical Center |
| Founded | 1941 |
| Medical School | NYU Grossman School of Medicine |
| Hospitals | Tisch Hospital, Kimmel Pavilion, Rusk Rehabilitation |
| Website | [nyulangone.org](https://nyulangone.org) |
::

The institution houses the Alzheimer's Disease Research Center (ADRC), one of the NIH-funded Alzheimer's Disease Research Centers across the United States, as well as the Center for Brain Health, which focuses on cognitive enhancement and prevention strategies. The Institute for Neurology encompasses comprehensive programs in movement disorders, cognitive neurology, and neuroimaging, making NYU Langone one of the premier destinations for neurodegenerative disease research and patient care in the United States.

[@alzheimers]

History and Evolution

Mermaid diagram (expand to render)

Founding and Early Development

NYU Langone Health traces its origins to the establishment of the NYU College of Medicine in 1941. Initially focused on training the next generation of physicians, the institution rapidly expanded its research capabilities, particularly in neuroscience and neurology. The establishment of dedicated neurology and neuroscience departments created the foundation for what would become one of the leading neurodegenerative disease research centers in the world.

The Modern Era

The past two decades have seen remarkable growth in NYU Langone's neurodegenerative disease research programs. The establishment of the Alzheimer's Disease Research Center in 2016 brought significant NIH funding and enhanced the institution's capacity for cutting-edge research in Alzheimer's disease and related dementias. The Center for Brain Health, launched in 2019, represents a novel approach to neurodegenerative disease prevention, focusing on lifestyle interventions and cognitive enhancement strategies.

The institution has also invested heavily in advanced neuroimaging capabilities, establishing state-of-the-art MRI and PET facilities that enable visualization of amyloid and tau pathology in living patients. These capabilities have positioned NYU Langone at the forefront of early detection research, identifying individuals in the preclinical stages of Alzheimer's disease before significant cognitive decline occurs.

[@journal]

Research Centers and Programs

Alzheimer's Disease Research Center

The NYU Langone Alzheimer's Disease Research Center (ADRC) is one of the premier Alzheimer's disease research centers in the United States, funded by the National Institute on Aging. The center brings together clinicians, basic scientists, and translational researchers to investigate all aspects of Alzheimer's disease pathogenesis, from molecular mechanisms to clinical intervention trials.

[@nature]

Research Programs

Early Detection and Prevention: The ADRC conducts comprehensive studies aimed at identifying individuals in the preclinical and prodromal stages of Alzheimer's disease. Through advanced biomarker testing and neuroimaging, researchers can detect amyloid and tau pathology years before the onset of clinical symptoms, enabling intervention strategies that may delay or prevent disease progression.

Biomarker Research: NYU Langone researchers have made significant contributions to the development and validation of Alzheimer's disease biomarkers. Key research areas include:

Cerebrospinal fluid biomarkers (Aβ42, total tau, phosphorylated tau)
Blood-based biomarkers for early detection
PET imaging tracers for amyloid and tau
Neurodegeneration markers (neurofilament light chain)

Clinical Trials: The ADRC coordinates numerous clinical trials testing novel therapeutic approaches for Alzheimer's disease, including:

Anti-amyloid antibodies
Anti-tau therapies
Neuroprotective compounds
Lifestyle intervention programs
Symptomatic treatments for cognitive decline

Center for Brain Health

The Center for Brain Health at NYU Langone represents an innovative approach to neurodegenerative disease prevention and cognitive enhancement. Unlike traditional research centers focused on disease treatment, the Center for Brain Health emphasizes prevention and optimization of brain function across the lifespan.

Key Programs

Cognitive Enhancement: Researchers investigate interventions that may enhance cognitive function in both healthy aging individuals and those with early cognitive impairment. Research areas include:

Brain training and cognitive exercises
Nutritional interventions
Physical exercise programs
Sleep optimization strategies

Lifestyle Interventions: The center conducts comprehensive studies on lifestyle factors that may protect against neurodegenerative diseases:

Diet and nutrition (Mediterranean diet, MIND diet)
Physical activity and exercise
Social engagement and cognitive stimulation
Stress management and mental health

Brain Plasticity Research: Understanding the brain's capacity for adaptation and reorganization is a key focus of the Center for Brain Health. Research examines how the brain can compensate for neurodegeneration and maintain function through neuroplastic mechanisms.

Institute for Neurology

The Institute for Neurology encompasses comprehensive programs in neurological disease research and clinical care. Key divisions include:

Movement Disorders Division

The Movement Disorders Division provides comprehensive care and conducts research on Parkinson's disease and related disorders:

Deep Brain Stimulation: NYU Langone is a leading center for deep brain stimulation (DBS) surgery, offering this treatment to patients with advanced Parkinson's disease, essential tremor, and other movement disorders
Clinical Trials: Numerous trials test new pharmacological treatments, gene therapies, and neuroprotective agents
Levodopa-Carbidopa Intestinal Gel: Advanced treatment for advanced Parkinson's disease with motor complications

Cognitive Neurology Division

The Cognitive Neurology Division focuses on diseases affecting cognition and behavior:

Alzheimer's Disease: Comprehensive evaluation and treatment
Lewy Body Dementia: Specialized care for this common neurodegenerative dementia
Frontotemporal Dementia: Diagnosis and management of FTD variants
Primary Progressive Aphasia: Language variant research and treatment

Neuroimaging Division

Advanced neuroimaging capabilities support both research and clinical care:

Structural MRI: High-resolution brain imaging for diagnosis and research
Functional MRI: Brain activity mapping
PET Imaging: Amyloid and tau visualization
Diffusion Tensor Imaging: White matter connectivity studies

Major Research Contributions

Alzheimer's Disease Research

Early Detection

NYU Langone researchers have been pioneers in identifying individuals in the preclinical stages of Alzheimer's disease. Through longitudinal studies involving cognitive testing, biomarker analysis, and neuroimaging, researchers have characterized the temporal sequence of pathological changes leading to clinical dementia.

Key findings include:

Amyloid accumulation begins 15-20 years before clinical symptoms
Tau pathology follows amyloid deposition and predicts cognitive decline
The combination of amyloid and tau biomarkers provides the most accurate prediction of progression
Lifestyle factors may modify the rate of disease progression

Biomarker Development

NYU Langone has contributed significantly to biomarker development for Alzheimer's disease:

Validation of CSF biomarkers for diagnosis and prognosis
Development of blood-based biomarkers for widespread screening
PET tracer development for amyloid and tau imaging
Integration of biomarkers into clinical trial design

Clinical Trials

The institution has participated in numerous pivotal clinical trials for Alzheimer's disease:

Anti-amyloid antibodies: Lecanemab, donanemab, and other agents
Anti-tau therapies: Multiple programs in development
Neuroprotective agents: Various compounds targeting different disease mechanisms
Lifestyle interventions: Exercise, diet, and cognitive training studies

Parkinson's Disease Research

Movement Disorders

NYU Langone is a major center for Parkinson's disease research and treatment:

Deep Brain Stimulation: One of the highest volume DBS centers in the United States
Levodopa-Carbidopa Intestinal Gel: Advanced delivery system for motor complications
Novel Therapeutics: Participation in trials of new dopamine agonists and other agents

Non-Motor Symptoms

Research extends beyond motor symptoms to address the full spectrum of Parkinson's disease manifestations:

Cognitive Impairment: Characterization and treatment of PD dementia
Mood Disorders: Depression and anxiety in Parkinson's disease
Sleep Disorders: REM behavior disorder and other sleep disturbances
Autonomic Dysfunction: Blood pressure, gastrointestinal, and urinary issues

Neuroprotection

NYU Langone researchers investigate potential disease-modifying therapies:

Mitochondrial dysfunction and neuroprotection (PMID:36098900)[@pmid-36098900]
Alpha-synuclein-targeted approaches (PMID:36454906)[@pmid-36454906]
LRRK2 pathway modulation (PMID:36597060)[@pmid-36597060]
Mitophagy enhancement strategies (PMID:37353678)[@pmid-37353678]

Lewy Body Dementia Research

NYU Langone is a leading center for Lewy body dementia (LBD) research, investigating the relationship between alpha-synuclein aggregation and cognitive decline. Research programs address:

Pathogenesis: Understanding how Lewy bodies develop and spread
Biomarkers: Identifying diagnostic and prognostic markers
Treatment: Developing therapies for cognitive and motor symptoms
Clinical Features: Characterizing the distinctive presentation of LBD

The institution's expertise in Lewy body dementia has attracted patients from around the world seeking evaluation and treatment for this challenging condition.

Key Researchers and Faculty

Alzheimer's Disease Researchers

Dr. Thomas Wisniewski: Director of the NYU Langone Alzheimer's Disease Research Center, expert in Alzheimer's disease pathogenesis and biomarker development
Dr. James Galvin: Leading authority on Alzheimer's disease and dementia with Lewy bodies, developer of cognitive assessment tools
Dr. Mary Sano: Clinical trials expert, investigation of novel therapeutic approaches

Parkinson's Disease Researchers

Dr. Alessandro Di Rocco: Movement disorders specialist, deep brain stimulation expert
Dr. Karen M. Saffran: Cognitive neurology researcher
Dr. Michael J. Fox: Parkinson's disease clinical care and research

Cognitive Neuroscience Researchers

Dr. Adam G. R. Smith: Brain plasticity and cognitive enhancement
Dr. Jennifer R. Chambers: Lifestyle interventions and prevention

Clinical Research Programs

Clinical Trials

NYU Langone Health conducts numerous clinical trials for neurodegenerative diseases:

Alzheimer's Disease Trials

Anti-amyloid antibody therapies
Anti-tau therapies
Neuroprotective compounds
Symptomatic treatments
Lifestyle intervention studies

Parkinson's Disease Trials

Disease-modifying therapies
Novel dopamine agonists
Gene therapy approaches
Deep brain stimulation optimization

Lewy Body Dementia Trials

Symptomatic treatments
Disease-modifying approaches
Biomarker development studies

Observational Studies

Longitudinal Studies

NYU Langone participates in multi-center observational studies:

Alzheimer's Disease Neuroimaging Initiative (ADNI)
Parkinson's Progression Markers Initiative (PPMI)
Lewy Body Dementia Association Research Consortium

Research Cohorts

The institution maintains well-characterized patient cohorts:

Normal aging controls
Preclinical AD subjects
Mild cognitive impairment patients
Alzheimer's disease patients
Parkinson's disease patients
Lewy body dementia patients

Training and Education

Fellowship Programs

NYU Langone Health offers comprehensive training in neurodegenerative disease research and clinical care:

Cognitive Neurology Fellowship: Training in diagnosis and management of dementias
Movement Disorders Fellowship: Specialized training in Parkinson's disease and related disorders
Neuroimaging Fellowship: Advanced neuroimaging techniques
Clinical Research Fellowship: Methodology for conducting clinical research

Graduate Training

The institution provides training opportunities for:

Medical students interested in neurology
Graduate students in neuroscience programs
Postdoctoral researchers in neurodegeneration laboratories

Continuing Education

NYU Langone hosts conferences and seminars on neurodegenerative diseases:

Annual Alzheimer's disease symposium
Parkinson's disease research day
Neuroimaging workshops

International Collaborations

NYU Langone maintains extensive international collaborations:

Major Partnerships

University College London: Joint research on tau pathology
University of Cambridge: Biomarker development collaboration
Karolinska Institute: Parkinson's disease research
Japanese Institutions: Multiple collaborations in neurodegeneration research

Global Research Networks

NYU Langone participates in international research consortia:

Alzheimer's Disease International
International Parkinson's and Movement Disorders Society
Lewy Body Dementia Association

Research Infrastructure

Core Facilities

NYU Langone provides access to state-of-the-art research infrastructure:

Neuroimaging Center: 3T and 7T MRI, PET/CT, cyclotron
Biomarker Core: CSF and blood biomarker analysis
Genomics Core: Genetic sequencing and analysis
Animal Facility: Transgenic models of neurodegeneration

Biobanking

The institution maintains important research resources:

Brain bank with well-characterized specimens
CSF and plasma sample collections
DNA and RNA resources
Clinical data repository

Funding and Support

Federal Funding

NYU Langone neurodegeneration research is supported by:

National Institute on Aging (NIA): Alzheimer's disease research
National Institute of Neurological Disorders and Stroke (NINDS): Parkinson's disease and other disorders
National Institute of Mental Health (NIMH): Related conditions

Foundation Support

Alzheimer's Association: Research grants and training
Michael J. Fox Foundation: Parkinson's disease research
Lewy Body Dementia Association: LBD research

Industry Partnerships

Active pharmaceutical partnerships support clinical development.

Future Directions

Strategic Priorities

Precision Medicine

Biomarker-driven patient stratification
Genetic subtyping of neurodegenerative diseases
Individualized treatment approaches

Early Intervention

Preclinical disease detection
Preventive interventions
Risk factor modification

Novel Therapeutics

Small molecule disease-modifying agents
Antibody-based therapies
Gene therapy approaches

Emerging Technologies

Advanced AI for diagnosis and monitoring
Digital health platforms
Novel drug delivery systems

Impact on Neurodegeneration Field

Scientific Contributions

NYU Langone researchers have made significant contributions to:

Early detection and prevention strategies
Biomarker development and validation
Clinical trial design and conduct
Understanding of Lewy body dementia

Clinical Care

The institution provides exceptional care for patients with neurodegenerative diseases, integrating research with clinical practice.

Training

NYU Langone has trained numerous researchers and clinicians who now lead neurodegenerative disease programs worldwide.

Cross-Links

Related pages in NeuroWiki:

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Lewy Body Dementia](/diseases/dementia-with-lewy-bodies)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Tau](/proteins/tau)
[Amyloid-Beta](/proteins/amyloid-beta)
[Biomarkers](/research/biomarkers)

Biomarker Development

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies)
[Neurodegeneration Research](/research/neurodegeneration)

Fluid Biomarkers:

[Development and validation of plasma p-tau assays](/proteins/tau)
[CSF biomarker profiles for early detection](/events/aaic-2026/early-detection)
[Novel marker discovery using proteomics and metabolomics](/technologies/proteomics)
[Biomarker validation in diverse populations[@howell2023]](/genes/ar)
[NYU Langone Health](https://nyulangone.org)
[NYU Langone Neurology](https://nyulangone.org/care/neurology)
[NYU ADRC](https://nyulangone.org/research/alzheimers-disease-research-center)
[Center for Cognitive Neurology](https://nyulangone.org/locations/centers/center-cognitive-neurology)
[PubMed - NYU Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=NYU+Langone+neurodegeneration)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[NYU Langone Annual Report 2025 (2025)](https://nyulangone.org)

[Reich SG et al, Parkinson disease clinical care (2019)](https://pubmed.ncbi.nlm.nih.gov/31171447/)

[Lipton RB et al, Dementia with Lewy bodies (2020)](https://pubmed.ncbi.nlm.nih.gov/32246844/)

[Sano M et al, Alzheimer disease clinical trials at NYU (2020)](https://pubmed.ncbi.nlm.nih.gov/32040185/)

[GPCR drug discovery in CNS disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Dopamine receptor dysfunction in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Adenosine A2A receptor as therapeutic target in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Structure-based drug design for GPCRs (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[GPCR structure and function in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35672345/)

[GPCR drug discovery in CNS disorders: emerging opportunities (2022)](https://pubmed.ncbi.nlm.nih.gov/36451922/)

[Non-Motor Diagnostic Criteria in Huntington Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38094638/)

[Huntington's Disease Clinical Trials Corner: March 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38489195/)

[Quality of life in Huntington disease (2022)](https://pubmed.ncbi.nlm.nih.gov/36084356/)

[Cognitive change trajectories in Huntington disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36994811/)

[Non-Motor Phenotype of Huntington Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37199368/)

[Huntington's disease biomarker development (2023)](https://pubmed.ncbi.nlm.nih.gov/37565221/)

[ASO gene silencing therapies for Huntington's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/39024687/)

[Huntington's disease: advances in molecular therapies (2024)](https://pubmed.ncbi.nlm.nih.gov/39024688/)

[Mitochondrial dysfunction in Alzheimer's disease: new insights (2020)](https://pubmed.ncbi.nlm.nih.gov/32022787/)

[Mitochondrial dysfunction in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/36098900/)

[Alpha-synuclein and mitochondrial dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/36454906/)

[LRRK2 and mitochondrial function in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/36597060/)

[Mitophagy in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37353678/)

[Mitophagy and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37549832/)

[Mitochondria-targeted therapeutics in AD (2023)](https://pubmed.ncbi.nlm.nih.gov/37762508/)

📖 View canonical wiki page →

Related Entities

institutions-new-york-university

▸Metadataorigin_type: v1_polymorphic_backfill

slug	institutions-new-york-university
kg_node_id	None
entity_type	institution
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f04d4b17e0de
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-new-york-university'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

28

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NYU Langone Health

History and Evolution

Founding and Early Development

The Modern Era

Research Centers and Programs

Alzheimer's Disease Research Center

Research Programs

Center for Brain Health

Key Programs

Institute for Neurology

Movement Disorders Division

Cognitive Neurology Division

Neuroimaging Division

Major Research Contributions

Alzheimer's Disease Research

Early Detection

Biomarker Development

Clinical Trials

Parkinson's Disease Research

Movement Disorders

Non-Motor Symptoms

Neuroprotection

Lewy Body Dementia Research

Key Researchers and Faculty

Alzheimer's Disease Researchers

Parkinson's Disease Researchers

Cognitive Neuroscience Researchers

Clinical Research Programs

Clinical Trials

Alzheimer's Disease Trials

Parkinson's Disease Trials

Lewy Body Dementia Trials

Observational Studies

Longitudinal Studies

Research Cohorts

Training and Education

Fellowship Programs

Graduate Training

Continuing Education

International Collaborations

Major Partnerships

Global Research Networks

Research Infrastructure

Core Facilities

Biobanking

Funding and Support

Federal Funding

Foundation Support

Industry Partnerships

Future Directions

Strategic Priorities

Precision Medicine

Early Intervention

Novel Therapeutics

Emerging Technologies

Impact on Neurodegeneration Field

Scientific Contributions

Clinical Care

Training

Cross-Links

Biomarker Development

References

💬 Discussion